Development and characterization of iPSC-derived regulatory T cells – Towards an allogenic cell therapy for the treatment of autoimmunity and inflammatory conditions

Regulatory T cells (Tregs) play a pivotal role in maintaining immune homeostasis and preventing autoimmunity. Treg-based cell therapies have already shown efficient modulation of immune responses in several clinical settings. However, the complexity and the cost of manufacturing autologous cell products restricts their implementation to certain patient populations with the highest unmet need. Induced pluripotent stem cells (iPSCs) have emerged as suitable starting material for generating diverse cell types, including Tregs.